TUB 030
Alternative Names: TUB-030Latest Information Update: 07 Aug 2024
At a glance
- Originator Tubulis
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Aug 2024 Tubulis plans a clinical trial for Solid tumours
- 09 Apr 2024 Interim pharmacodynamics and adverse events data from a preclinical studies in solid tumours released by Tubulis
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research 2024 (AACR-2024)